Ongoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events, no ...

Invivyd had also attempted to attain regulatory approval for pemivibart.Credit: Design_Cells via Shutterstock. At IDWeek 2025, (the joint annual meeting of the Infectious Diseases Society of America, ...

New FDA approval language for COVID-19 vaccines is sowing confusion about which conditions put people at greater risk for severe disease and who can avoid the inconvenience and cost of off-label ...

The updated NCCN Guidelines now include the recommendation for monoclonal antibodies for pre-exposure prophylaxis against COVID-19, highlighting the significance of Invivyd's products in cancer care.

Invivyd's monoclonal antibody (mAb) VYD2311 is a prophylactic for COVID has greater efficacy and less side effects than COVID vaccines. The current administration's clear goal of minimizing the ...

Interim data captured from a phase 3 trial suggest pemivibart may be effective prophylaxis against COVID-19 infection for high-risk patients with significant immunocompromising conditions who continue ...

Looking for information about the FDA’s limited approval of 2025-26 COVID vaccines? Read what we know about who can get an updated COVID shot this year. Updated Aug. 27 If it feels like several people ...

Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or ...

A new clinical trial found azelastine cut COVID-19 infections by 70%, hinting at a cheap, accessible way to add protection alongside vaccines. Let’s be honest: when it comes to COVID-19 prevention, ...